Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics

IF 3.2 3区医学 Q3 ONCOLOGY

Seminars in Radiation Oncology Pub Date : 2025-09-09 DOI:10.1016/j.semradonc.2025.08.004

Maria Farooq , Michael J. Pishvaian

引用次数: 0

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies with dismal 5-year survival rates. Characterized by its complex tumor microenvironment and resistance to conventional therapies, PDAC has historically been difficult to treat effectively. Recent advances in molecular profiling have revolutionized our understanding of the genetic landscape of pancreatic cancer. This review examines how molecular genetics is driving precision medicine approaches in pancreatic cancer, with particular focus on KRAS-targeted therapies. Understanding these developments is crucial for clinicians seeking to optimize treatment strategies and improve outcomes for patients with pancreatic cancer.

查看原文本刊更多论文

分子遗传学推动胰腺癌精准医疗

胰腺导管腺癌（PDAC）仍然是最致命的恶性肿瘤之一，其5年生存率低。PDAC肿瘤微环境复杂，对常规治疗有耐药性，历来难以有效治疗。分子图谱的最新进展彻底改变了我们对胰腺癌遗传格局的理解。这篇综述探讨了分子遗传学如何推动胰腺癌的精准医学方法，特别关注kras靶向治疗。了解这些发展对于寻求优化治疗策略和改善胰腺癌患者预后的临床医生至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in Radiation Oncology 医学-核医学

CiteScore

5.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Each issue of Seminars in Radiation Oncology is compiled by a guest editor to address a specific topic in the specialty, presenting definitive information on areas of rapid change and development. A significant number of articles report new scientific information. Topics covered include tumor biology, diagnosis, medical and surgical management of the patient, and new technologies.